IBANDRONATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ibandronate, and what generic alternatives are available?
Ibandronate is a drug marketed by Accord Hlthcare, Apotex, Avet Lifesciences, Chemi Spa, Eugia Pharma, Nang Kuang Pharm Co, Pharmobedient, Sun Pharm, Apotex Inc, Aurobindo Pharma, Dr Reddys Labs Ltd, Macleods Pharms Ltd, Orbion Pharms, Sun Pharm Industries, and Watson Labs Teva. and is included in sixteen NDAs.
The generic ingredient in IBANDRONATE is ibandronate sodium. There are sixteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the ibandronate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ibandronate
A generic version of IBANDRONATE was approved as ibandronate sodium by APOTEX INC on March 19th, 2012.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for IBANDRONATE?
- What are the global sales for IBANDRONATE?
- What is Average Wholesale Price for IBANDRONATE?
Summary for IBANDRONATE
| US Patents: | 0 |
| Applicants: | 15 |
| NDAs: | 16 |
| Drug Prices: | Drug price information for IBANDRONATE |
| DailyMed Link: | IBANDRONATE at DailyMed |
US Patents and Regulatory Information for IBANDRONATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accord Hlthcare | IBANDRONATE SODIUM | ibandronate sodium | INJECTABLE;INTRAVENOUS | 206058-001 | Feb 5, 2016 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Pharmobedient | IBANDRONATE SODIUM | ibandronate sodium | INJECTABLE;INTRAVENOUS | 202671-001 | Sep 2, 2014 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Chemi Spa | IBANDRONATE SODIUM | ibandronate sodium | INJECTABLE;INTRAVENOUS | 202235-001 | Sep 2, 2014 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Macleods Pharms Ltd | IBANDRONATE SODIUM | ibandronate sodium | TABLET;ORAL | 206887-001 | Oct 31, 2017 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sun Pharm | IBANDRONATE SODIUM | ibandronate sodium | INJECTABLE;INTRAVENOUS | 090853-001 | Feb 14, 2014 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Watson Labs Teva | IBANDRONATE SODIUM | ibandronate sodium | TABLET;ORAL | 079003-001 | Mar 20, 2012 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
